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Youngmok Park1, Eun Hye Lee1, Inkyung Jung2, Goeun Park2 and Young Ae Kang1*Abstract
Background: Macrolide is a key drug in the treatment of Mycobacterium avium complex pulmonary disease (MAC-
PD). Macrolide-resistant MAC is gaining importance, but there are little data in clinical characteristics and treatment
outcomes of macrolide-resistant MAC-PD (MR-MAC-PD).
Methods: We performed a systematic review and meta-analysis of published studies reporting clinical
characteristics and treatment outcomes of patients with MR-MAC-PD. Risk of bias was assessed using the modified
Newcastle-Ottawa Scale.
Results: Nine studies (seven retrospective and two prospective) comprising 319 patients were identified through a
database search. Around 73% were women, and 52% had the fibrocavitary form. Pooled sputum culture conversion
rate after combined multiple antibiotics or surgical resection was 21% (95% confidence interval [CI], 14–30%), and
the one-year all-cause mortality was 10% (95% CI, 5–20%). There was no significant difference in treatment
outcomes between nodular bronchiectatic and fibrocavitary types.
Conclusions: Even combination therapy with fluoroquinolone, aminoglycoside, and surgical resection, the
treatment outcomes of MR-MAC-PD were poor. The investigation of new treatment modalities is urgent.
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ClarithromycinBackground
The incidence and prevalence of nontuberculous myco-
bacterial (NTM) pulmonary disease are increasing
worldwide [1–3]. Mycobacterium avium complex
(MAC), mainly comprising M. avium and M. intracellu-
lare, has been reported as the most common etiology of
NTM pulmonary disease in many countries such as
North America and East Asia [3].© The Author(s). 2019 Open Access This artic
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Full list of author information is available at the end of the articleMacrolides, such as clarithromycin and azithromycin,
are indispensable to the antibiotic treatment of MAC
pulmonary disease (MAC-PD). A macrolide-based multi-
drug regimen comprising ethambutol and rifamycin has
been recommended as the first-line therapy for patients
with MAC-PD [1, 2, 4]. However, the development of
macrolide resistance indicated poor treatment outcomes
and increased mortality [5–8], similar to the prognosis
of multidrug-resistant tuberculosis (MDR-TB) [7].
Only a few studies with a limited number of patients
have evaluated the clinical characteristics and treatment
outcomes of macrolide-resistant MAC-PD (MR-MAC-
PD), and the results were inconsistent in terms of risk
factors and optimal treatment modalities. The differentle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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to inconsistency in treatment success. Conducting a pro-
spective controlled study with a large number of patients
is challenging because the development of macrolide re-
sistance is unpredictable, and there is no evidence-based
treatment regimen in MR-MAC-PD. Therefore, in the
present study, we aimed to understand the clinical char-
acteristics and treatment outcomes of MR-MAC-PD
through a systematic review and meta-analysis.
Methods
This study was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses guidelines [9]. The protocol was registered on
PROSPERO (registration number: CRD42019118499).
Search strategies
We searched Medline, Embase, Cochrane library, and
ProQuest databases to identify full-length articles pub-
lished up to August 25, 2019. The search strategy for
each database is presented in Additional file 2: Table S1,
S2, S3, and S4. Duplicates, as well as case reports, re-
views, conference abstracts, newspaper articles, nonclini-
cal studies, and animal studies were excluded. English
studies were selected.
Eligibility criteria
The inclusion criterion was original studies on MR-
MAC-PD patients without human immunodeficiency
virus (HIV) infection. Relevant studies were independ-
ently selected by two reviewers (Y Park and EH Lee).
The authors initially screened the articles by title and ab-
stract, and then assessed the full text as needed. Studies
with less than 5 patients were excluded. No restrictions
were applied regarding study design or methods of data
collection (prospective or retrospective).
Data extraction and quality assessment
Two coding authors (Y Park and EH Lee) extracted data
from the selected publications with a pre-defined data ex-
traction form. The following information was recorded:
study characteristics (authors, setting, study design, cri-
teria for macrolide resistance), patient characteristics (age,
sex, radiologic types, etc.), and treatment outcomes (spu-
tum culture conversion and the one-year all-cause mortal-
ity rate). Study quality was assessed using a modified
Newcastle-Ottawa Scale [10]. The one-year all-cause mor-
tality rate provided with Kaplan-Meier curve was obtained
by digitizing the figure using the online software Web Plot
Digitizer [11].
Statistical analysis
Pooled estimates and 95% CI were calculated using ei-
ther fixed-effects or random-effects model.Heterogeneity was quantified in terms of Q- and I2-sta-
tistics. If a significant heterogeneity was present (P-
values for Q-statistics < 0.10) [12], pooled estimates from
random-effects models were reported. Publication bias
was assessed using a funnel plot. We used R (v. 3.6.0) in
all statistical analyses.
Results
Study selection and identified studies
A total of 4221 studies were identified from the database
search. Among them, 3420 publications were selected
after comparison of results and de-duplication. The se-
lected studies were screened by title, abstract, and full
text. Figure 1 shows the selection process and exclusion
criteria. Finally, we included nine studies on MR-MAC-
PD in this meta-analysis [5–8, 13–17].
The identified studies and their key characteristics are
listed in Table 1. There were two prospective studies,
and the other seven studies were of retrospective de-
scriptive design. A total of 319 patients were eligible for
the analysis. In eight studies, MAC isolates with a clari-
thromycin minimal inhibitory concentration ≥ 32 μg/mL
in the broth microdilution method were defined as
macrolide-resistant.
Clinical characteristics
The mean age of the patients ranged from 65 to 68
years, and the proportion of women ranged from 32 to
100% (Table 1). The pooled estimate for the proportion
of women was 73% (95% Confidence interval [CI], 53–
86%, Fig. 2a) with random-effects model; I2 statistic was
84%, and Q-statistic was 31.2 (P < 0.001), indicating a
high level of heterogeneity.
Five studies reported the percentage of fibrocavitary
(FC) type of the disease. The pooled estimate was 52%
(95% CI, 37–67%, Fig. 2B) with random-effects model;
the I2 statistic was 76%, and Q-statistic was 21.4 (P <
0.001), representing substantial heterogeneity. Four stud-
ies [5–7, 14] reported the proportion of M. avium and
M. intracellulare separately, and the percentage of M.
avium ranged from 23 to 100% (Table 1).
As we excluded the studies with HIV infected subjects,
most patients had chronic lung diseases such as asthma,
chronic obstructive pulmonary disease, bronchiectasis,
chronic pulmonary aspergillosis, or history of pulmonary
tuberculosis.
Sputum culture conversion rate and the one-year all-
cause mortality rate
The definition of sputum culture conversion in each
study is described in Table 2. The reported sputum cul-
ture conversion rate ranged from 11% [7, 16] to 38%
[15], and the overall pooled estimate with random-
effects model was 21% (95% CI, 14–30%, Fig. 3a). The I2
Fig. 1 Flowchart describing the selection of studies included in the analysis. Abbreviations: MAC, M. avium complex pulmonary disease; HIV,
human immunodeficiency virus
Park et al. Respiratory Research          (2019) 20:286 Page 3 of 10statistic was 57%, and the Q-statistic was 20.3 (P =
0.009).
The one-year all-cause mortality rate was reported in
four studies (Fig. 3b). It ranged from 0 to 25% [5], and
the pooled estimate was 10% (95% CI, 5–20%) with I2
statistic of 53% and Q-statistic of 9.60 (P = 0.048).
We conducted a subgroup analysis by radiologic types
of MAC-PD. Four studies reported the sputum culture
conversion rate between nodular bronchiectatic (NB)
and FC types. The estimated odds ratio for sputum cul-
ture conversion in NB type compared with the FC type
was 0.56 (95% CI, 0.24–1.30, Additional file 1: Fig. S1A).Three studies reported the odds ratios for the one-year
all-cause mortality rate in NB to FC type: 2.20 (95% CI,
0.61–7.99) [5]; 0.15 (95% CI, 0.01–3.19) [6]; and 0.06 (95%
CI, 0.00–1.23) [7]. The pooled estimate was 0.38 (95% CI,
0.03–4.30) with random-effects model (Additional file 1:
Fig. S1B); the interpretation needs caution owing to the
limited number of studies.
Treatment modalities of MR-MAC-PD
According to the studies of Tanaka et al. [13] and Grif-
fith et al. [5], more than half of the patients with MR-
MAC-PD were treated with macrolide monotherapy or a
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Fig. 2 Clinical characteristics of patients with macrolide-resistant M. avium complex pulmonary disease. Forest plots for (a) female proportion and
(b) fibrocavitary (FC) type disease proportion. Note: A study by Aznar et al. [15] was excluded from this analysis because it is designed to match
sex and radiologic types
Park et al. Respiratory Research          (2019) 20:286 Page 5 of 10two-drug regimen comprising macrolides before the de-
tection of macrolide resistance. In contrast, patients
treated with standard multidrug regimen before the de-
velopment of macrolide resistance were also substantial
in the studies of Moon et al. (65%) and Morimoto et al.
(28%) [6, 7].
Treatment regimens after the detection of macrolide
resistance in each study are presented in Table 2. For
the treatment of MR-MAC-PD, new treatment perspec-
tives are tried, such as clofazimine, amikacin inhalation,
amikacin liposomal inhalation suspension (ALIS), and
surgery.
Assessment of methodological quality
When methodological quality was assessed using the
modified Newcastle-Ottawa Scale, most studies had a low
risk of bias for measurement of macrolide resistance, and
low to moderate risk of bias in the patient selection and
assessment of treatment outcomes (Additional file 2:
Table S5).
Discussion
Newer macrolides, including clarithromycin and azithro-
mycin, are cornerstones in the antibiotic treatment of
MAC-PD, and the development of macrolide resistance
is associated with poor treatment outcomes [4]. How-
ever, there are limited studies on treatment modalities
and outcomes for MR-MAC-PD. In this study, we aimedto understand the clinical characteristics and treatment
outcomes of MR-MAC-PD through a systematic review
and meta-analysis, and found that the overall sputum
culture conversion rate was 21% (95% CI, 14–30%), and
the one-year all-cause mortality rate was 10% (95% CI,
5–20%). There were no differences in sputum culture
conversion rate and the one-year all-cause mortality rate
between NB and FC type of MR-MAC-PD.
The treatment of MAC-PD is complicated, and the
treatment results are not satisfactory. Even in macrolide-
susceptible MAC-PD, the treatment success rate with
macrolide containing multidrug regimens ranged from
60% [18] to 65.7% [19]. Sustained sputum culture con-
version rate with macrolide-free regimens was 38% in a
previous systematic review [20]. In our present study,
the pooled estimate of sputum culture conversion rate
was 21% (95% CI, 14–30%), which represents a worse
treatment outcome of MR-MAC-PD. Pan et al. reported
that microbiologic persistence in patients with MAC-PD
could lead to an increased risk of radiographic progres-
sion [21]. In the same perspective, low sputum culture
conversion rate in MR-MAC-PD could be a predictor of
disease progression including radiographic progression.
Patients with MAC-PD are at a significant risk of
death. Diel et al. [22] reported a pooled estimate of the
five-year all-cause mortality rate of patients with MAC-
PD as 27% (95% CI, 21–33%). Moon et al. [6] and Mori-
moto et al. [7] reported five-year all-cause mortality
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Fig. 3 Treatment outcomes of patients with macrolide-resistant M. avium complex pulmonary disease. Forest plots for (a) sputum culture
conversion rate and (b) one-year all-cause mortality rate
Park et al. Respiratory Research          (2019) 20:286 Page 8 of 10rates of MR-MAC-PD as 47 and 29%, respectively. The
pooled estimate of the one-year mortality rate was 10%
(95% CI, 5–20%) in this study. Several studies have dem-
onstrated the incremental impact of NTM infection on
mortality [23–25]; however, the assessment of NTM-
related mortality is difficult because the proportion of
deaths attributed to NTM infection depends mostly on
how clinicians decide the cause of death. In addition,
there are limited data on the mortality of MR-MAC-PD
compared to the general population and patients with
macrolide-susceptible MAC-PD. Considering the
chronic features of NTM infection, long-term mortality
assessment is necessary for patients with MR-MAC-PD.
Morimoto et al. [7] compared the treatment outcome of
MR-MAC-PD to that of 311 patients with MDR-TB; the
5-year survival rates between the two groups were similar
(71% vs. 75%, P = 0.6). MDR-TB is considered a severe
health concern worldwide. The World Health
Organization reported that only 55% of patients with
MDR-TB in 2015 successfully completed medication; the
treatment failed in 8% of the patients, and 15% died [26].
There are a few explanations for the emergence of
macrolide resistance in MAC-PD. First, inappropriate
regimen as first-line treatment may trigger macrolide re-
sistance. Griffith et al. [5] reported that the majority
(76%) of patients with MR-MAC-PD started their initial
treatment with macrolide monotherapy or the combin-
ation of a macrolide and a fluoroquinolone. Morimoto
et al. [7] showed that 60.2% of patients did not receive
proper multidrug regimens, such as clarithromycinmonotherapy, clarithromycin plus fluoroquinolone, and
regimens without ethambutol. Moon et al. [6] also re-
ported that one-third of the population did not receive
ethambutol owing to its adverse events.
Second, relatively low concentrations of core drugs
and high bacterial burden have been suggested as an ex-
planation for macrolide resistance. Concomitant use of
rifamycin is related to reduced serum levels of macro-
lide, particularly clarithromycin [27, 28]. Moon et al. [6]
and Kadota et al. [8] reported that macrolide resistance
can occur even when patients were treated with proper
multidrug regimen, because a small proportion of pa-
tients received macrolide monotherapy (32% in the study
of Moon et al. and 18% in the study of Kadota et al., re-
spectively) or a two-drug combination with a macrolide
(33% in the study of Moon et al. and 12% in the study of
Kadota et al., respectively).
There is no proven treatment modality for MR-MAC-
PD yet. Maintenance of macrolide after the detection of
macrolide resistance is frequent. Surgical intervention
and prolonged parenteral aminoglycoside administration
are the primary treatment strategies for the treatment of
MR-MAC-PD (Table 2). The recent British Thoracic So-
ciety guidelines recommend adding another drug such
as isoniazid, moxifloxacin, or nebulized amikacin for
treatment of MR-MAC-PD. However, the efficacy of
these treatment regimens remains inconclusive [2]. Re-
cently, clofazimine, bedaquiline, and ALIS have been
used for the treatment of refractory MAC-PD, including
MR-MAC-PD [16, 29, 30]. In the CONVERT study [16],
Park et al. Respiratory Research          (2019) 20:286 Page 9 of 10a prospective open-label, randomized study for the treat-
ment of patients with refractory MAC-PD, ALIS with
guideline-based therapy (GBT) showed culture conver-
sion rate of 29.0% compared to 8.9% of GBT alone.
Among MR-MAC-PD group, culture conversion was
achieved by 13.7% of patients in the ALIS + GBT arm
and 4.5% in the GBT-alone arm. Even this latest ALIS
therapy, treatment outcome of MR-MAC-PD was poor.
Bedaquiline was also recently tried as a treatment option
for refractory NTM-PD, although the study was prelim-
inary and the number of patients was small [29]. There-
fore, for the treatment of MR-MAC-PD, new drugs or
new pharmaceutical formulations of existing drugs
should be investigated.
This is the first study to integrate the clinical charac-
teristics and treatment outcomes of patients with MR-
MAC-PD. Nevertheless, this study has several limita-
tions. First, because only a small number of studies were
enrolled in this analysis, we could not thoroughly evalu-
ate the publication bias. Second, all the studies had no
control group, and most of them were retrospective ob-
servational design. Therefore, we should interpret the re-
sults with caution. Third, the treatment outcomes were
estimated from the various treatment modalities because
there was no uniform protocol for the treatment of MR-
MAC-PD. Fourth, we could not evaluate the long-term
treatment outcomes of MR-MAC-PD owing to the rela-
tively short follow-up duration of each study. In
addition, we could not assess treatment outcomes in-
cluding clinical and radiographic improvement.
In conclusion, the treatment outcomes of MR-MAC-
PD were poor, the overall sputum culture conversion
rate was 21% (95% CI, 14–30%), and the one-year all-
cause mortality rate was 10% (95% CI, 5–20%). Despite
the combination of multiple antibiotics including ALIS
and surgical resection, the outcomes of MR-MAC-PD
were poor The investigation of new treatment modalities
is urgent for the treatment of MR-MAC-PD.
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